Spark Investment Management’s Surmodics SRDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
Sell
-8,121
Closed -$353K 688
2019
Q1
$353K Sell
8,121
-25,079
-76% -$1.28M 0.02% 435
2018
Q4
$1.57M Hold
33,200
0.11% 241
2018
Q3
$2.48M Buy
33,200
+9,100
+38% +$627K 0.14% 216
2018
Q2
$1.33M Buy
24,100
+12,500
+108% +$577K 0.08% 315
2018
Q1
$441K Buy
11,600
+3,200
+38% +$99.1K 0.03% 415
2017
Q4
$235K Hold
8,400
0.01% 549
2017
Q3
$260K Sell
8,400
-16,100
-66% -$438K 0.01% 573
2017
Q2
$689K Sell
24,500
-7,400
-23% -$179K 0.04% 454
2017
Q1
$767K Hold
31,900
0.05% 461
2016
Q4
$810K Sell
31,900
-9,100
-22% -$239K 0.07% 381
2016
Q3
$1.23M Hold
41,000
0.1% 291
2016
Q2
$962K Hold
41,000
0.09% 311
2016
Q1
$754K Hold
41,000
0.08% 355
2015
Q4
$831K Buy
41,000
+15,700
+62% +$333K 0.11% 270
2015
Q3
$552K Buy
25,300
+14,100
+126% +$331K 0.07% 359
2015
Q2
$261K Hold
11,200
0.04% 472
2015
Q1
$291K Buy
+11,200
New +$267K 0.04% 470
2013
Q3
Sell
-15,300
Closed -$306K 587
2013
Q2
$306K Buy
+15,300
New +$383K 0.08% 290

Other funds holding SRDX

Spark Investment Management's SRDX Position: Q2 2019 in Review

Spark Investment Management sold out of Surmodics (SRDX) in Q2 2019, closing a stake of 8,121 shares — an estimated $353K sold.

Spark Investment Management first reported a position in SRDX in Q2 2013 and held it in 18 quarters. The position peaked at $2.48M in Q3 2018. 140 funds tracked by Wall St. Rank hold SRDX as of Q2 2019.

  • Spark Investment Management reported no remaining Surmodics position as of Q2 2019 after selling out during the quarter.
  • Spark Investment Management sold 8,121 Surmodics shares in Q2 2019, an estimated $353K.
  • Spark Investment Management first reported a position in Surmodics in Q2 2013 and held it in 18 quarters.
  • Spark Investment Management's Surmodics position peaked at $2.48M in Q3 2018.
  • 140 funds tracked by Wall St. Rank held Surmodics as of Q2 2019.

Based on Spark Investment Management's 13F filing for Q2 2019, filed 12 Aug 2019.